Molbio Diagnostics IPO

Published: 5 August 2026 | 8.00 AM
Last Updated: 5 August 2026 | 8.30 PM

IPO Snapshot

Investor Decision Box

Chanakya View

Molbio Diagnostics IPO offers investors exposure to one of India’s differentiated molecular diagnostics businesses. Its principal attraction is the proprietary Truenat platform, a portable PCR-based point-of-care molecular diagnostics system designed to deliver rapid testing even in resource-constrained locations.

The financial performance is impressive. Total income increased from Rs. 1,027.94 crore in FY25 to Rs. 1,455.17 crore in FY26, a growth of about 42%. PAT increased from Rs. 138.58 crore to Rs. 164.14 crore, while EBITDA reached Rs. 328.24 crore.

However, there are two important considerations. At the upper price of Rs. 807, Molbio commands a market capitalisation of approximately Rs. 9,300 crore, so investors are paying for its technology platform and future growth prospects.

Secondly, approximately Rs. 740 crore of the Rs. 940 crore IPO is Offer for Sale (OFS). Therefore, most of the issue proceeds will go to existing selling shareholders rather than the company.

Chanakya Recommendation: 🟢 Apply, particularly for investors comfortable with growth-oriented healthcare businesses. Listing-gain investors should additionally monitor GMP and subscription trends during 10–12 August.

About Molbio Diagnostics

Incorporated in 2000, Molbio Diagnostics Limited is a point-of-care molecular diagnostics company engaged in research, development, manufacturing and commercialisation of diagnostic solutions for infectious and non-communicable diseases.

Its flagship Truenat platform is a portable, battery-operated PCR-based molecular diagnostics system capable of providing accurate test results within approximately one hour.

Molbio provides molecular testing solutions covering more than 30 diseases through 43 diagnostic assays, including tuberculosis, COVID-19, HIV, Hepatitis B & C and HPV.

The company operates six manufacturing facilities in India and serves customers across more than 90 countries. Its customers include government health programmes, hospitals, diagnostic laboratories and international healthcare organisations.

Why This IPO Stands Out

✅ Proprietary Truenat molecular diagnostics platform with differentiated point-of-care technology.

✅ Presence across 90+ countries, providing the business with significant international reach.

✅ Portfolio covering 30+ diseases through 43 diagnostic assays.

✅ Strong FY26 growth, with total income increasing approximately 42%.

✅ Recurring demand potential from diagnostic test kits used with the installed testing platform.

✅ Fresh IPO proceeds support further R&D and manufacturing infrastructure investment.

Key Risks

⚠ The IPO contains a large Rs. 739.70 crore OFS, compared with a fresh issue of only about Rs. 200 crore.

⚠ Borrowings increased sharply from Rs. 123.16 crore in FY25 to Rs. 412.64 crore in FY26.

⚠ PAT margin declined from 13.48% to 11.28%, despite strong revenue growth.

⚠ ROCE declined from 20.98% in FY25 to 17.55% in FY26.

⚠ The diagnostics industry requires continuous R&D investment and faces technological, regulatory and competitive risks.

Financial Snapshot – Rs. Crore

Chanakya Interpretation: Molbio has demonstrated an excellent three-year growth trajectory. From FY24 to FY26, total income increased from Rs. 840.66 crore to Rs. 1,455.17 crore, while PAT nearly doubled from Rs. 83.54 crore to Rs. 164.14 crore.

The concern is that FY26 growth came with margin moderation and substantially higher borrowings. Investors should therefore assess future earnings growth rather than relying only on headline revenue expansion.

Business Quality Score

Part 1 conclusion: Molbio Diagnostics combines proprietary technology, strong revenue growth, international presence and an attractive diagnostics opportunity. The principal watchpoints are valuation, rising debt, margin moderation and the large OFS component. GMP and subscription response should determine how aggressively investors approach the issue.